利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.019 秒)

    LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES
    21.
    发明授权
    LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES 失效
    脂质球对于受控物品供应

    公开(公告)号：EP0502119B1

    公开(公告)日：1996-01-31

    申请号：EP91901106.4

    申请日：1990-11-08

    申请人： SCIOS NOVA, INC.

    发明人： DOMB, Abraham, J. ,  MANIAR, Manoj

    IPC分类号： A61K9/16 ,  A61K9/50 ,  A01N25/26

    CPC分类号： A01N25/26 ,  A61K9/127 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/167 ,  A61K9/5015

    摘要： Solid, water-insoluble lipospheres formed of a solid hydrophobic core having a layer of a phospholipid embedded on the surface of the core, containing biologically active agent in the core, in the phospholipid, adhered to the phospholipid, or a combination thereof, are disclosed for use in providing extended release of active agent, including drugs such as vaccines and anesthetics, insect control agents such as insecticides and repellents, and agricultural compounds such as fertilizers, fungicides, pesticides, and herbicides. Lipospheres can be prepared by a melt technique or a solvent technique, summarized as: (1) forming a liquid solution or suspension of the agent by either melting the agent, or dissolving or dispersing the agent in a liquid vehicle, to form a mixture of liquid agent that solidifies at room temperature or greater; (2) adding phospholipid and an aqueous solution to the liquid agent to form a suspension; (3) mixing the suspension at a temperature above the melting temperature until a homogeneous fine dispersion is obtained; and then (4) rapidly cooling the dispersion to below the melting temperature of the liquid mixture containing the agent. Agent can also be added to the phospholipid or mixed with the resulting lipospheres. The agent containing lipospheres have several advantages over other delivery systems, including emulsions, vesicles and liposomes, including stability, low cost of reagents, ease of manufacture, high dispersibility in an aqueous medium, a release rate for the entrapped substance that is controlled by the phospholipid coating and the carrier. Examples demonstrate the effective administration of anesthetics, antigens, and insect repellent (DEET).

    Recombinant alveolar surfactant protein
    25.
    发明公开
    Recombinant alveolar surfactant protein 失效
    重组蛋白Alveolar-oberflächenaktives蛋白。

    公开(公告)号：EP0251449A2

    公开(公告)日：1988-01-07

    申请号：EP87303919.2

    申请日：1987-04-30

    申请人： SCIOS NOVA INC.

    发明人： Schilling, James W. ,  White, Robert T. ,  Cordell, Barbara ,  Benson, Bradley J.

    IPC分类号： C12N15/12 ,  C12P21/02 ,  A61K38/00 ,  C07K14/00

    CPC分类号： C12N15/85 ,  A61K38/00 ,  C07K14/785 ,  C12P21/02

    摘要： The complete coding sequence and amino acid sequences for both canine and human 10K alveolar surfactant proteins (ASP) are disclosed; clones encoding variants of the SP-18 and SP-5 forms of human protein are disclosed. Methods and vectors for obtaining these proteins in recombinantform are also described. An improved method for purification of the 32K protein takes advantage of its carbohydrate affinity.Pharmaceutical compositions in the treatment of respiratory deficiency syndromes use the 10K proteins with or without the 32K form.

    摘要翻译： 公开了犬和人10K肺泡表面活性蛋白（ASP）的完整编码序列和氨基酸序列; 公开了编码SP-18和SP-5形式的人蛋白质的变体的克隆。 还描述了用于获得重组形式的这些蛋白质的方法和载体。 用于纯化32K蛋白质的改进方法利用其碳水化合物亲合力。治疗呼吸缺陷综合征的药物组合物使用具有或不具有32K形式的10K蛋白质。

    BRADYKININ TYPE PEPTIDES
    29.
    发明公开
    BRADYKININ TYPE PEPTIDES 失效
    BRADYKININ TYPISCHE PEPTIDE。

    公开(公告)号：EP0618809A1

    公开(公告)日：1994-10-12

    申请号：EP92911377.0

    申请日：1992-04-16

    申请人： SCIOS NOVA INC.

    发明人： KYLE, Donald, James ,  HINER, Roger, Neal

    IPC分类号： A61K38 ,  A61P17 ,  A61P25 ,  A61P29 ,  C07D207 ,  C07K7

    CPC分类号： C07D207/12 ,  A61K38/00 ,  C07K7/18 ,  Y10S514/803 ,  Y10S530/807 ,  Y10S530/816

    摘要： Le remplacement du L-Pro à la position 7 par D-Phe ou D-Tic et le remplacement de L-Phe à la position 8 par des éthers d'hydroxyproline et des thioéthers de bradykinine et d'autres analogues substitués de bradykinine transforme les agonistes de la bradykinine en antagonistes de la bradykinine. L'invention porte également sur d'autres modifications, en d'autres positions des antagonistes de bradykinine modifiés en position 7 et 8, qui renforcent la résistance aux enzymes, la puissance antagoniste et/ou la spécificité des nouveaux antagonistes de bradykinine. Les analogues obtenus sont utiles pour le traitement des états pathologiques chez les mammifères et chez l'être humain souffrant d'un excès de bradykinine ou de kinines voisines induit, par exemple, par une piqûre d'insecte.